Article révisé par les pairs
Résumé : Prostaglandin F2α. (PGF2α) was determined by radioimmunoassay in 57 breast carcinomata, 16 fibroadenomata, and 33 sclero-cystic-disease (SCD) specimens. In 41 cases of carcinoma and 10 cases of fibroadenoma, histologically non-malignant tissue was also obtained from the same breast. PGF2α levels were significantly elevated in breast cancer when compared with the normal tissues and benign diseases (P<0.005 for each group). High PGF2α levels were positively correlated with differentiation, positive oestrogen and progestagen receptor status, and low mitotic index. Tumours with good prognosis (<20mm, negative lymph nodes, some degree of differentiation) showed significantly higher PGF2α levels than tumours with a bad prognosis(>20mm, positive nodes and undifferentiated). A tendency for elevated PGF2α levels was observed with negative lymphatic permeation, postmenopausal status, low grade of nuclear and cellular polymorphism and high degree of elastosis and fibrosis. No correlation was observed between PGF2α levels and host-cell reaction. Plasma levels of 15-keto-13, 14-dihydro-PGF2α, were not elevated in cancer patients when compared with the SCD-group. The present study demonstrates that PGF2α levels are high in tumours with good prognosis. However, since other authors have suggested that a high PGE2 production is a bad prognostic index, it is possible that conversion of PGE2 to PGF2α by 9-keto-reductase explains this relationship. Nevertheless, the presented results question the unrestricted use of prostaglandin-synthesis-inhibitors in the treatment of breast cancer. © 1985, The Macmillan Press Ltd.

Documents en relation

DI-fusion